Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A3088 | Mitazalimab (Anti-TNFRSF5 / CD40) | Mitazalimab (Anti-TNFRSF5 / CD40) a human agonist IgG1 antibody targeting CD40. It enhances the anti-tumour efficacy of a model cancer vaccine. MW: 143.44 KD. | Human IgG1 |
| A2833 | Donanemab (Anti-Amyloid Beta) | Donanemab (LY3002813) is a humanised IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD. | Human IgG1 |
| A3089 | Ravagalimab (Anti-TNFRSF5 / CD40) | Ravagalimab (Anti-TNFRSF5 / CD40) is a monoclonal antibody targeting CD40. It can be used for research of Crohn's disease. MW: 146.04 KD. | Human IgG1 |
| A2834 | Grisnilimab (Anti-CD7) | Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD. | Human IgG2SA |
| A2835 | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) | Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.18 KD. | Human IgG4SP |
| A3091 | Anti-GAD65 | Anti-GAD65 is an autoantibody targeting glutamic acid decarboxylase (GAD65). It is used in treatment of Stiff person syndrome (SPS). MW :146.38 KD. | Human IgG1 |
| A2836 | Iladatuzumab (Anti-CD79b) | Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD. | Human IgG1 |
| A3092 | Anti-MICB | Anti-MICB is an antibody that specifically targets human major histocompatibility complex class I chain-related A and B (MICA/B). It can be used in treating a cancer. MW: 143.66 KD. | Human IgG2SA |
| A2837 | Anti-CD83 | Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD. | Human IgG2SA |
| A3093 | Tabalumab (Anti-TNFSF13B / BAFF / CD257) | Tabalumab (Anti-TNFSF13B / BAFF / CD257) is a humanised monoclonal antibody BAFF (B-cell activating factor). It can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus. MW: 146.2 KD. | Human IgG4SP |
| A2838 | Anti-CD9 | Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumour activity. MW: 145.98 KD. | Human IgG1 |
| A3094 | Anti-TNFSF14 / LIGHT / CD258 (SAR252067) | Anti-TNFSF14 / LIGHT / CD258 (SAR252067) is a fully human monoclonal antibody targeting LIGHT. It can be used in treatment of treatment of ulcerative colitis and crohn's disease. MW :141.8 KD. | Human IgG1 |
| A2839 | Anti-CDH1 / E-cadherin / CD324 | Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD. | Human IgG1 |
| A3095 | Anti-TNFSF2 / TNFa (CDP571) | Anti-TNFSF2 / TNFa (CDP571) is an antibody targeting tumor necrosis factor (TNF). It can be used in the treatment of rheumatoid arthritis (RA). MW: 146.9 KD. | Human IgG4SP |
| A2841 | Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) | Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanized monoclonal antibody which targets Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with immunostimulating and antineoplastic activities. MW: 146.48 KD. | Human IgG1 |
| A3097 | Anti-TNFSF2 / TNFa (CMAB008) | Anti-TNFSF2 / TNFa (CMAB008) is an antibody targeting tumor necrosis factor (TNF). It can be used in the treatment of rheumatoid arthritis (RA). MW: 147.16 KD. | Human IgG1 |
| A2842 | Ebdarokimab (Anti-IL-12b) | Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW: 145.6 KD. | Human IgG1 |
| A3098 | Anti-TNFSF2 / TNFa (ESBA 105) | Anti-TNFSF2 / TNFa (ESBA 105) is an antibody targeting tumour necrosis factor (TNF). It has an efficient intraocular penetration to anterior and posterior region of eye. MW: 145.14 KD. | Human IgG1 |
| A2843 | Ebronucimab (Anti-PCSK9) | Ebronucimab (Anti-PCSK9) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used to treat hyperlipidaemia. MW: 144.76 KD. | Human IgG1 |
| A3099 | Anti-TNFSF2 / TNFa (hMAK195) | Anti-TNFSF2 / TNFa (hMAK195) is an antibody targeting tumor necrosis factor (TNF). It can be used in the treatment of rheumatoid arthritis (RA). MW: 145.06 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.